Zepbound subcutaneous injection 12.5mg Ateos

Zepbound subcutaneous injection 12.5mg Ateos, manufactured by Eli Lilly Japan, contains Tirzepatide. This long-acting GIP/GLP-1 receptor agonist is indicated for the treatment of obesity in adults with hypertension, dyslipidemia, or type 2 diabetes mellitus, who do not respond adequately to diet or exercise. It is provided as a 12.5mg 0.5mL 1 kit with YJ code 2499422P2020.